Alerts will be sent to your verified email
Verify Email
ASTRAZEN
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
Pfizer
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
18.6 % | 6.1 % | 4.8 % |
|
R&D as a % of Total Sales
|
0.0 | 0.0 | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
17.42 % | 17.74 % | 19.03 % |
|
5yr average Equity Multiplier
|
1.99 | 1.76 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.91 | 0.51 | 0.6 |
|
5yr Avg Net Profit Margin
|
9.65 % | 22.76 % | 26.04 % |
|
Price to Book
|
29.01 | 7.83 | 5.54 |
|
P/E
|
121.87 | 57.74 | 28.91 |
|
5yr Avg Cash Conversion Cycle
|
-6.33 Days | -54.68 Days | 21.86 Days |
|
Inventory Days
|
68.19 Days | 27.48 Days | 49.93 Days |
|
Days Receivable
|
35.81 Days | 54.07 Days | 29.1 Days |
|
Days Payable
|
187.52 Days | 148.48 Days | 77.28 Days |
|
5yr Average Interest Coverage Ratio
|
142.38 | 66.44 | 185.18 |
|
5yr Avg ROCE
|
23.84 % | 18.34 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
14.57 % | 34.43 % | 31.72 % |
|
5 yr average Debt to Equity
|
0.0 | 0.46 | 0.0 |
|
5yr CAGR Net Profit
|
4.4 % | -0.19 % | 76.68 % |
|
5yr Average Return on Assets
|
8.92 % | 12.4 % | 15.25 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 54.83 % | 63.92 % |
|
Share Pledged by Promoters
|
0.0 | 16.93 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 2.53 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.26 % | 6.42 % | 4.53 % |
|
Astrazeneca Pharma I
|
Eris Lifesciences
|
Pfizer
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|